Compounds > 9-aminocamptothecin
Page last updated: 2024-08-25

9-aminocamptothecin and Disease Exacerbation

9-aminocamptothecin has been researched along with Disease Exacerbation in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hochster, H; Mandeli, J; Muggia, FM; Plimack, ER; Runowicz, CD; Sorich, J; Speyer, J; Wadler, S; Wallach, RC; Wright, J1
Goldberg, RM; Hatfield, AK; Knost, JA; Krook, JE; Kugler, J; Mahoney, MR; Pitot, HC; Sargent, DJ1
Arbuck, S; Argiris, A; Cooper, DL; DiStasio, S; Foss, FM; Heald, P; Kuzel, T; Murren, JR1

Trials

3 trial(s) available for 9-aminocamptothecin and Disease Exacerbation

ArticleYear
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Camptothecin; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome

2004
A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma.
    Cancer, 2000, Oct-15, Volume: 89, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Time Factors

2000
Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma.
    Investigational new drugs, 2001, Volume: 19, Issue:4

    Topics: Adult; Antineoplastic Agents; Camptothecin; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neutropenia; Skin Neoplasms; Time Factors; Treatment Outcome

2001